Jump to content
RemedySpot.com

CD95/Ligand in CLL

Rate this topic


Guest guest

Recommended Posts

Guest guest

Leuk Lymphoma 2002 Apr;43(4):881-4

Humoral immunodeficiency in chronic lymphocytic

leukemia: role of CD95/CD95L in tumoral damage and

escape.

Sampalo A, Brieva JA.

Servicio de Inmunologia, Hospital Universitario Puerta

del Mar, Cadiz, Spain.

B cell chronic lymphocytic leukemia (B-CLL) is the

most frequent hematological neoplasm in the human

adult life. This tumor is often associated with

hypogammaglobulinemia and infections.

This review focuses on recently reported mechanisms

underlying the humoral immunodeficiency occurring in

B-CLL. Tumoral cells provoke several alterations to

normal regulatory T cells, which, in turn, can impair

the correct maturation of B cells. In addition, the

direct inhibitory effect of B-CLL cells on

immunoglobulin (Ig)-secreting plasma cells (PC) may

account for the humoral immunodeficiency.

This phenomenon is mediated by the interaction of

CD95L molecules expressed by B-CLL cells with the

death receptor CD95 that is up-regulated on patients'

PC, leading to PC apoptosis and subsequently to

hypogammaglobulinemia.

Furthermore, the presence of CD95L on B-CLL cells

could play an additional role in tumoral

immune-escape, as reported in other neoplasms.

PMID: 12153179 [PubMed - in process]

__________________________________________________

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...